Overview

CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).

Status:
Recruiting
Trial end date:
2025-09-10
Target enrollment:
Participant gender:
Summary
Clinical trial for the safety and efficacy of induction chemotherapy with VA regime and bridging CD19CD22 CAR-T therapy in adult patients with newly diagnosed high-risk and Ph- B-ALL
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Treatments:
Azacitidine
Venetoclax